ENHERTU

Roche’s VENTANA HER2 (4B5) test received CE-IVDR approval for expanded use in breast and biliary tract cancers. It’s the first companion diagnostic to identify HR-positive metastatic breast cancer patients with HER2-ultralow expression potentially eligible for ENHERTU treatment. It’s also approved to identify previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) patients who may be eligible for ZIIHERA. This strengthens Roche’s position in personalized cancer treatment, offering more targeted options for patients.